CAS: 339186-68-4 - Matuzumab
Formel:Unspecified
- Synonyme:
- Emd 62000
- Emd 7200
- Emd 72000
- Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal 425 γ1-chain), disulfide with human-mouse monoclonal 425 κ-chain, dimer
- Immunoglobulin G1, anti-(human epidermal growth factor receptor) (humanized MAb 425 γ1-chain), disulfide with humanized MAb 425 κ-chain, dimer
- Immunoglobulin G1, anti-(human epidermal growth factor receptor)(humanized MAb 425 gamma-1 chain), disulfide with humanized MAb 425 kappa-chain, dimer
- KGaA
- Matuzumab [INN]
- Merck KGaA
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | Matuzumab REF: TM-T9922CAS: 339186-68-4 | 98% | Nachfragen | Mo 03 Jun 24 |
 | Matuzumab - 10 mg/ml REF: 3D-BM165590CAS: 339186-68-4 | Min. 95 Area-% | 1.054,00 €~1.618,00 € | Di 11 Jun 24 |
Matuzumab
CAS:339186-68-4
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity …
Reinheit:
98%
Farbe und Form:
Solid
Molekulargewicht:
N/A
- Inhibitoren
- Angiogenese
- EGFR
- JAK/STAT-Signalweg
- Mehr Kategorien anzeigen
- Tyrosinkinase/Adaptoren
- PI3K/Akt/mTOR-Signalgebung
Ref: TM-T9922
| 5mg | Nachfragen |
Voraussichtliche Lieferung in Vereinigte Staaten, am Montag 3. Juni 2024
Matuzumab - 10 mg/ml
CAS:339186-68-4
Intereferes with EGFR homodimerisation; cancer therapy
Reinheit:
Min. 95 Area-%
Farbe und Form:
Powder
Ref: 3D-BM165590
| 1mg | 1.054,00 € | |
| 2mg | 1.296,00 € | |
| 5mg | 1.618,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 11. Juni 2024
